EDSA - CIK 0001540159
The table below shows Edesa Biotech, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q4 2025 | Q4 2024 | Q4 2023 | Q4 2022 | Q4 2021 | Q4 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$2.09M | -$1.52M | -$1.41M | -$1.79M | -$3.21M | -$3.01M |
| Capital expenditure | - | - | - | $0.00 | $3.14K | $1.14K |
| Investing cash flow | - | - | $0.00 | $0.00 | -$3.14K | -$1.14K |
| Dividends paid | - | - | - | - | - |
Edesa Biotech, Inc. reported operating cash flow of -$7.32M for fiscal year 2025. That is down 49.7% from -$4.89M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$4.41M (FY 2015) to -$7.32M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $3.36M | $2.07M | $305.74K | $2.91M | $1.23M | $1.99M |